Corrigendum: Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy

Vascular endothelial growth factor (VEGF) signals cell survival, cell migration, osteogenesis, cell proliferation, angiogenesis, and vascular permeability by binding to VEGF receptor 2 (VEGFR-2). Osteosarcoma is the most common primary bone cancer, majorly affects young adults. Activation of VEGFR-2...

Full description

Saved in:
Bibliographic Details
Main Authors: Velayutham, Naveen Kumar, Thamaraikani, Tamilanban, Wahab, Shadma, Khalid, Mohammad, Gobinath, Ramachawolran, Abullais, Shahabe Saquib, Wong, Ling Shing, Mahendran, Sekar, Gan, Siew Hua, Ebenezer, Angel Jemima, Ravikumar, Mrinalini, Vetriselvan, Subramaniyan *, Nur Najihah, Izzati Mat Rani, Wu, Yuan Seng *, Jeyabalan, Srikanth
Format: Article
Published: Frontiers Media 2024
Subjects:
Online Access:http://eprints.sunway.edu.my/2634/
https://doi.org/10.3389/fphar.2024.1343756
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Sunway University
id my.sunway.eprints.2634
record_format eprints
spelling my.sunway.eprints.26342024-05-20T05:59:54Z http://eprints.sunway.edu.my/2634/ Corrigendum: Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy Velayutham, Naveen Kumar Thamaraikani, Tamilanban Wahab, Shadma Khalid, Mohammad Gobinath, Ramachawolran Abullais, Shahabe Saquib Wong, Ling Shing Mahendran, Sekar Gan, Siew Hua Ebenezer, Angel Jemima Ravikumar, Mrinalini Vetriselvan, Subramaniyan * Nur Najihah, Izzati Mat Rani Wu, Yuan Seng * Jeyabalan, Srikanth QP Physiology RC Internal medicine Vascular endothelial growth factor (VEGF) signals cell survival, cell migration, osteogenesis, cell proliferation, angiogenesis, and vascular permeability by binding to VEGF receptor 2 (VEGFR-2). Osteosarcoma is the most common primary bone cancer, majorly affects young adults. Activation of VEGFR-2 signaling is a therapeutic target for osteosarcoma. The present study aimed to evaluate the potency of stylopine in regulation of the VEGFR-2 signaling pathway and its anti-tumour effect human MG-63 osteosarcoma cells. The in silico study on benzylisoquinoline alkaloids was carried out for analyzing and shortlisting of compounds using a virtual screening, Lipinski’s rule, bioavailability graphical RADAR plot, pharmacokinetics, toxicity, and molecular docking studies. Among the benzylisoquinoline alkaloids, stylopine was selected and subjected to in-vitro studies against human MG-63 osteosarcoma cells. Various experiments such as MTT assay, EtBr/AO staining, mitochondrial membrane potential assessment, transwell migration assay, gene expression analysis by a quantitative real time polymerase chain reaction (qRT-PCR) method, SDS-PAGE followed by immunoblotting were performed to evaluate its anti-tumour effect as compared to standard axitinib. The MTT assay indicates that stylopine inhibits cell proliferation in MG-63 cells. Similarly, as confirmed by the EtBr/Ao staining method, the MMP assay indicates that stylopine induces mitochondrial membrane damage and apoptosis as compared to axitinib. Moreover, stylopine inhibits the VEGF-165 induced MG-63 cell migration by a trans-well migration assay. The immunoblotting and qRT-PCR analysis showed that stylopine inhibits the VEGF-165 induced VEGFR2 expression in MG-63 cells. It is concluded that stylopine has potential to regulate VEGFR2 and can inhibit osteosarcoma cells to offer a new drug candidate for the treatment of bone cancer in future. Frontiers Media 2024 Article PeerReviewed Velayutham, Naveen Kumar and Thamaraikani, Tamilanban and Wahab, Shadma and Khalid, Mohammad and Gobinath, Ramachawolran and Abullais, Shahabe Saquib and Wong, Ling Shing and Mahendran, Sekar and Gan, Siew Hua and Ebenezer, Angel Jemima and Ravikumar, Mrinalini and Vetriselvan, Subramaniyan * and Nur Najihah, Izzati Mat Rani and Wu, Yuan Seng * and Jeyabalan, Srikanth (2024) Corrigendum: Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy. Frontiers in Pharmacology, 15. ISSN 1663-9812 https://doi.org/10.3389/fphar.2024.1343756 10.3389/fphar.2024.1343756
institution Sunway University
building Sunway Campus Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Sunway University
content_source Sunway Institutional Repository
url_provider http://eprints.sunway.edu.my/
topic QP Physiology
RC Internal medicine
spellingShingle QP Physiology
RC Internal medicine
Velayutham, Naveen Kumar
Thamaraikani, Tamilanban
Wahab, Shadma
Khalid, Mohammad
Gobinath, Ramachawolran
Abullais, Shahabe Saquib
Wong, Ling Shing
Mahendran, Sekar
Gan, Siew Hua
Ebenezer, Angel Jemima
Ravikumar, Mrinalini
Vetriselvan, Subramaniyan *
Nur Najihah, Izzati Mat Rani
Wu, Yuan Seng *
Jeyabalan, Srikanth
Corrigendum: Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy
description Vascular endothelial growth factor (VEGF) signals cell survival, cell migration, osteogenesis, cell proliferation, angiogenesis, and vascular permeability by binding to VEGF receptor 2 (VEGFR-2). Osteosarcoma is the most common primary bone cancer, majorly affects young adults. Activation of VEGFR-2 signaling is a therapeutic target for osteosarcoma. The present study aimed to evaluate the potency of stylopine in regulation of the VEGFR-2 signaling pathway and its anti-tumour effect human MG-63 osteosarcoma cells. The in silico study on benzylisoquinoline alkaloids was carried out for analyzing and shortlisting of compounds using a virtual screening, Lipinski’s rule, bioavailability graphical RADAR plot, pharmacokinetics, toxicity, and molecular docking studies. Among the benzylisoquinoline alkaloids, stylopine was selected and subjected to in-vitro studies against human MG-63 osteosarcoma cells. Various experiments such as MTT assay, EtBr/AO staining, mitochondrial membrane potential assessment, transwell migration assay, gene expression analysis by a quantitative real time polymerase chain reaction (qRT-PCR) method, SDS-PAGE followed by immunoblotting were performed to evaluate its anti-tumour effect as compared to standard axitinib. The MTT assay indicates that stylopine inhibits cell proliferation in MG-63 cells. Similarly, as confirmed by the EtBr/Ao staining method, the MMP assay indicates that stylopine induces mitochondrial membrane damage and apoptosis as compared to axitinib. Moreover, stylopine inhibits the VEGF-165 induced MG-63 cell migration by a trans-well migration assay. The immunoblotting and qRT-PCR analysis showed that stylopine inhibits the VEGF-165 induced VEGFR2 expression in MG-63 cells. It is concluded that stylopine has potential to regulate VEGFR2 and can inhibit osteosarcoma cells to offer a new drug candidate for the treatment of bone cancer in future.
format Article
author Velayutham, Naveen Kumar
Thamaraikani, Tamilanban
Wahab, Shadma
Khalid, Mohammad
Gobinath, Ramachawolran
Abullais, Shahabe Saquib
Wong, Ling Shing
Mahendran, Sekar
Gan, Siew Hua
Ebenezer, Angel Jemima
Ravikumar, Mrinalini
Vetriselvan, Subramaniyan *
Nur Najihah, Izzati Mat Rani
Wu, Yuan Seng *
Jeyabalan, Srikanth
author_facet Velayutham, Naveen Kumar
Thamaraikani, Tamilanban
Wahab, Shadma
Khalid, Mohammad
Gobinath, Ramachawolran
Abullais, Shahabe Saquib
Wong, Ling Shing
Mahendran, Sekar
Gan, Siew Hua
Ebenezer, Angel Jemima
Ravikumar, Mrinalini
Vetriselvan, Subramaniyan *
Nur Najihah, Izzati Mat Rani
Wu, Yuan Seng *
Jeyabalan, Srikanth
author_sort Velayutham, Naveen Kumar
title Corrigendum: Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy
title_short Corrigendum: Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy
title_full Corrigendum: Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy
title_fullStr Corrigendum: Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy
title_full_unstemmed Corrigendum: Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy
title_sort corrigendum: stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (vegfr2) in osteosarcoma therapy
publisher Frontiers Media
publishDate 2024
url http://eprints.sunway.edu.my/2634/
https://doi.org/10.3389/fphar.2024.1343756
_version_ 1800100329826549760